Last reviewed · How we verify
NCT04625569: Naload
Genetic of Response to Acute Saline Load Test in Hypertension (Naload)
trial in Hypertension,Essential in 150 participants. Currently enrolling.
8 July 2023
Quick facts
| Lead sponsor | Ospedale San Raffaele |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 8 July 2019 |
| Primary completion | 8 July 2023 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Hypertension,Essential — all drugs for Hypertension,Essential →
- Salt; Excess — all drugs for Salt; Excess →
- Genetic Hypertension — all drugs for Genetic Hypertension →
- Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →
Sponsor
Ospedale San Raffaele — full company profile →
Who can join
Adults 18 to 65, any sex, with Hypertension,Essential or Salt; Excess. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NHP referred to our outpatient clinic will be enrolled (150 newly recruited) in acute saline test for phenotype characterisation of PNat relationship(7). For each patient we will collect urine and blood samples for standard clinical biochemistry, including electrolytes, creatinine, EO, aldosterone, plasma renin activity, urinary uromodulin (ELISA), urinary and serum uric acid and blood samples for genetic test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04625569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension,Essential
Currently open trials in the same condition.
- NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06205628 — Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension · Phase 1 · active not recruiting
- NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
- NCT04613193 — Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis · NA · recruiting
Other Ospedale San Raffaele trials
Trials by the same sponsor.
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT06922266 — Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option · not yet recruiting
- NCT06541834 — Predicting the Risk of Diabetic Neurodegenerative Disorders by Artificial Intelligence Tools Based on Retinal Imaging · recruiting
- NCT06229613 — Exhaled Breath Aerosol for the Etiological Diagnosis of Respiratory Tract Infections: a Pilot Study · completed
- NCT05675592 — Trikafta/Kaftrio and Pseudomonas Aeruginosa · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04625569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ospedale San Raffaele
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04625569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing